2 results
Approved WMOCompleted
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
Approved WMORecruiting
The primary objective is to determine if repeated GON-injection result in effective control of cluster headache attacks for more months compared to placebo in chronic cluster headache. Secondary objectives are to determine:- If the effect of one GON…